SecBot SecBot
COURT-RULING ·Filed Apr 16, 2026

TEVA

Teva Pharmaceuticals International Gmbh
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago CourtCourt Ruling · courtlistener.com
Court ruling (appellate)
Actionable Insight ▲ Bullish

Traders should view this as a major win for Teva's patent enforcement strategy; potential for positive stock reaction and increased valuation of its migraine franchise. Monitor for subsequent damages calculations or settlement discussions with Lilly.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.26
T+0 close · Apr 16, 2026 · via day close
Latest settled
+5.42%
T+60 · $32.95
Vs SPY
−2.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $31.26entry
  2. T+1 · 7mo ago +3.62%α +2.40% · $32.39
  3. T+5 · 7mo ago −0.19%α −1.18% · $31.20
  4. T+20 · 6mo ago +15.98%α +10.16% · $36.25
  5. T+60 · 4mo ago +5.42%α −2.18% · $32.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment invalidating Teva's headache-related patents, reinstating a jury verdict that Eli Lilly willfully infringed the patents. This strengthens Teva's IP position and may lead to damages or licensing revenue.

Court Ruling Details

Ruling Date
Apr 16, 2026
Court
United States Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Prost
Case Type
patent
Ruling Type
final judgment
Outcome
WIN: ruling favors this company
Damages Range
$100M-$500M+ (estimated based on Emgality sales)
Appeal Timeline
6-12 months for SCOTUS petition
Precedent Risk
LOW
Market Cap Exposure
0.27%

Key Facts

  • Federal Circuit reversed lower court's invalidation of Teva's U.S. Patent Nos. 8,586,045, 9,884,907, and 9,884,908
  • Appellate court reinstated jury finding that Eli Lilly willfully infringed the patents
  • Ruling affirms validity of Teva's patents covering use of humanized anti-CGRP antagonist antibodies to treat headache
  • Case remanded for further proceedings consistent with the opinion
  • Costs awarded to Teva

Financial Impact

Potential for significant damages award and/or future royalty income from Lilly's Emgality product, which generated $1.8B in 2025

revenueepsintellectual_property_value

Risk Factors

  • Lilly may appeal to Supreme Court
  • Lower court may still limit damages on remand
  • Potential for future challenges to patent scope

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-2pxskqsa-TEVA

Track record

61 reports on TEVA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens in 6h 46m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Apr 16, 2026